Gabriel Tremblay Health Economist

Mister Tremblay and his partnerteam offer a broad range of Health Economics and Economic Evaluation services to the pharmaceutical industry Biotech companies Research centers private or public payers and governments Mister Tremblay is Based in the US and in Canada and offers countrywide services Health Economics Services Health Economics for Submissions for drugs and devices US payers CADTH NICE EU5 Socioeconomic proofofconcept for health genetics drugs or personalized medicine projects Advanced modeling disease modeling advanced markov model microsimulation Health Economics for Oncology Ophan drugs public health economics Personalized medicine and genetic project health economics Development of QALY HE using patient reported outcomes PRO My priorities as a consultant in health economics 1 Customer service I strive to always be available when my clients need me with quick turnaround for urgent projects 2 Valuable health economic analysis I am transparent when communicating potential limitations of an analysis and provide exceptional value to my clients The highest quality standards are applied to all my work whether oneday projects or longterm studies 3 Robust and

Gabriel Tremblay Health Economist is a professional consulting practice providing a broad range of Health Economics and Economic Evaluation services for the pharmaceutical and biotech industries, research centers, private or public payers, and government stakeholders. Serving clients from the U.S. and Canada with countrywide coverage, the firm supports teams preparing evidence for drug and device submissions and helps decision-makers evaluate the value of health technologies. Core expertise includes Health Economics for submissions and evaluation contexts such as U.S. payers, CADTH, NICE, and EU5 pathways, as well as socioeconomic proof-of-concept for health genetics, personalized medicine, and related projects. The practice also delivers advanced modeling approaches including disease modeling, advanced Markov models, and microsimulation—especially in areas like oncology and orphan drugs. For outcomes and measurement, Gabriel Tremblay Health Economist focuses on the development of QALY frameworks using patient-reported outcomes (PRO) and supports public health economics and personalized medicine and genetic project health economics. Built on clear priorities, the consulting approach emphasizes customer service with quick turnaround for urgent projects, transparent communication about potential limitations, and consistently high-quality standards across both one-day and long-term studies. The goal is to provide robust, well-communicated evidence that helps clients demonstrate the value of their treatment options to healthcare systems, patients, and payers—an especially relevant need in the Houston, Texas market where data-driven decisions support effective care.